Further research also showed that brusatol decreased the viability and sensitized CRC cells to irinotecan toxicity, and abrogated CRC tumor growth in subcutaneously and orthotopically-allografted mice through inhibiting Nrf2 84. The gene discussed is NFE2L2; the disease is neoplasm.